Chemistry:Mibefradil

From HandWiki
Short description: Withdrawn antihypertensive drug of the calcium channel blocker class
Mibefradil
Mibefradil.svg
Clinical data
Trade namesPosicor
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa607007
Routes of
administration
By mouth (tablets)
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Bioavailability70%
Protein binding>99%
MetabolismLiver (CYP3A4)
Elimination half-life17–25 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC29H38FN3O3
Molar mass495.639 g·mol−1
3D model (JSmol)
Melting point128 °C (262 °F) (dihydrochloride salt)
 ☒N☑Y (what is this?)  (verify)

Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.[1]

The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels,[1] which is probably responsible for many of its unique properties.[citation needed]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.[2]

Synthesis

Mibefradil synthesis: YU patent 22988 ZW patent 20087

References